Literature DB >> 12117740

Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice.

Uwe J F Tietge1, Cyrille Maugeais, Sissel Lund-Katz, David Grass, Frederick C deBeer, Daniel J Rader.   

Abstract

OBJECTIVE: Plasma levels of high density lipoprotein (HDL) cholesterol and apolipoprotein (apo)A-I are decreased in inflammatory states. Secretory phospholipase A2 (sPLA2), an acute-phase protein, may play a key role in the pathophysiology of this phenomenon. METHODS AND
RESULTS: To investigate the effects of sPLA2 on human-like HDL particles in vivo, we generated transgenic mice overexpressing human apoA-I and human sPLA2 (apoA-I/sPLA2 mice). Compared with apoA-I mice, apoA-I/sPLA2 mice had significantly lower plasma levels of phospholipids, HDL cholesterol, and apoA-I (each P<0.01). HDL from apoA-I/sPLA2 mice was significantly depleted in phospholipids and cholesteryl esters (each P<0.001) but was enriched in protein and triglycerides (each P<0.001). As assessed by gel filtration and nondenaturing gel electrophoresis, sPLA2 overexpression in apoA-I mice resulted in a dramatic shift of the HDL particle size toward smaller particles. Furthermore, virtually all plasma sPLA2 in apoA-I/sPLA2 mice was found in association with the HDL fraction. The acute-phase response was induced in apoA-I/sPLA2 double-transgenic and apoA-I single-transgenic mice by intraperitoneal lipopolysaccharide (LPS) injection. Plasma sPLA2 was significantly increased after LPS injection in apoA-I/sPLA2 mice. Twelve hours after LPS administration, plasma total cholesterol, HDL cholesterol, apoA-I, and phospholipids were unchanged in apoA-I transgenic control mice but had decreased significantly in the apoA-I/sPLA2 mice (-57%, -62%, and -54%, -61%, respectively; each P<0.001). Both groups of mice had increased plasma levels of serum amyloid A (SAA) in response to LPS. To test the hypothesis that SAA may be an in vivo activator of sPLA2, we specifically overexpressed SAA in apoA-I/sPLA2 mice by means of liver-directed gene transfer. Despite high plasma levels of SAA, plasma lipid and lipoprotein profiles were not different than those in control mice.
CONCLUSIONS: These results in a mouse model of human-like HDL indicate that sPLA2 expression significantly influences HDL particle size and composition and demonstrate that an induction of sPLA2 is required for the decrease in plasma HDL cholesterol in response to inflammatory stimuli in mice and that this effect is independent of SAA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117740     DOI: 10.1161/01.atv.0000023228.90866.29

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  44 in total

1.  HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Anna M Kucharska-Newton; Wayne D Rosamond; Jane C Schroeder; Ann Marie McNeill; Josef Coresh; Aaron R Folsom
Journal:  Lung Cancer       Date:  2008-03-14       Impact factor: 5.705

2.  Featured Article: Alterations of lecithin cholesterol acyltransferase activity and apolipoprotein A-I functionality in human sickle blood.

Authors:  Eric Soupene; Mark S Borja; Mauricio Borda; Sandra K Larkin; Frans A Kuypers
Journal:  Exp Biol Med (Maywood)       Date:  2016-06-27

3.  Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats.

Authors:  Zhenghao Zhang; Geeta Datta; Yun Zhang; Andrew P Miller; Paulina Mochon; Yiu-Fai Chen; John Chatham; G M Anantharamaiah; C Roger White
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-06-26       Impact factor: 4.733

4.  Elevated apolipoprotein A-I levels are associated with favorable prognosis in metastatic nasopharyngeal carcinoma.

Authors:  Rou Jiang; Zhong-Han Yang; Dong-Hua Luo; Ling Guo; Rui Sun; Qiu-Yan Chen; Pei-Yu Huang; Fang Qiu; Xiong Zou; Ka-Jia Cao; Hai-Qiang Mai; Xiang Guo; Chao-Nan Qian; Ming-Huang Hong; Ming-Yuan Chen
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

5.  Paradoxical effects of SAA on lipoprotein oxidation suggest a new antioxidant function for SAA.

Authors:  Shobini Jayaraman; Christian Haupt; Olga Gursky
Journal:  J Lipid Res       Date:  2016-10-15       Impact factor: 5.922

Review 6.  Unraveling the complexities of the HDL lipidome.

Authors:  Anatol Kontush; Marie Lhomme; M John Chapman
Journal:  J Lipid Res       Date:  2013-03-30       Impact factor: 5.922

7.  Proteolysis of apolipoprotein A-I by secretory phospholipase A₂: a new link between inflammation and atherosclerosis.

Authors:  Giorgio Cavigiolio; Shobini Jayaraman
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

8.  Featured Article: Depletion of HDL3 high density lipoprotein and altered functionality of HDL2 in blood from sickle cell patients.

Authors:  Eric Soupene; Sandra K Larkin; Frans A Kuypers
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-24

9.  HDL Mimetic Peptide Administration Improves Left Ventricular Filling and Cardiac output in Lipopolysaccharide-Treated Rats.

Authors:  Geeta Datta; Himanshu Gupta; Zhenghao Zhang; Palgunachari Mayakonda; G M Anantharamaiah; C Roger White
Journal:  J Clin Exp Cardiolog       Date:  2011-12-22

10.  Inflammation impairs reverse cholesterol transport in vivo.

Authors:  Fiona C McGillicuddy; Margarita de la Llera Moya; Christine C Hinkle; Michelle R Joshi; Elise H Chiquoine; Jeffrey T Billheimer; George H Rothblat; Muredach P Reilly
Journal:  Circulation       Date:  2009-02-16       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.